Ginkgo biloba: An adjuvant therapy for progressive normal and high tension glaucoma

Molecular Vision

Volumn 18, Issue , 2012, Pages 390-402

  Cybulska Heinrich, A K ^a   Mozaffarieh, M ^a   Flammer, J ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; FLAVONOID; GINKGO BILOBA EXTRACT; GINKGOLIDE B; HEPARIN; MITOCHONDRIAL DNA; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; REACTIVE OXYGEN METABOLITE; WARFARIN;

ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTITHROMBOTIC ACTIVITY; ANTIVASOSPASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOREGULATION; BLEEDING; BLOOD RHEOLOGY; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; GLAUCOMA; HIGH TENSION GLAUCOMA; HISTOPATHOLOGY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LOW TENSION GLAUCOMA; MICROCIRCULATION; MITOCHONDRION; NEUROPROTECTION; NONHUMAN; OPTIC NERVE DISEASE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPERFUSION INJURY; RETINA GANGLION CELL; RETINA ISCHEMIA; RISK FACTOR; VASOSPASM; VISUAL FIELD DEFECT;

ANIMALS; CHEMOTHERAPY, ADJUVANT; EYE; GINKGO BILOBA; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; LOW TENSION GLAUCOMA; MICE; OPTIC NERVE DISEASES; OXIDATIVE STRESS; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 84857859399     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (95)

1. Bachinskaya N, Hoerr R, Ihl R. Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761. Findings from a randomized controlled trial. Neuropsychiatr Dis Treat 2011; 7:209-15. [PMID: 21573082]
2. Li S, Tang D, Xue Z, Zhang Z, Sun X, Liu Y, Dong H, Yin X, Zhang Z. Biphasic effect of EGb761 on simulated ischemia- induced rat BMSC survival in vitro and in vivo. Life Sci 2011; 88:853-63. [PMID: 21439976]
3. Janssen IM, Sturtz S, Skipka G, Zentner A, Garrido MV, Busse R. Ginkgo biloba in Alzheimer's disease: a systematic review. Wien Med Wochenschr 2010; 160:539-46. [PMID: 21170694]
4. de Lima KC, Schilichting CL, Junior LA, da Silva FM, Benetoli A, Milani H. The Ginkgo biloba extract, EGb 761, fails to reduce brain infarct size in rats after transient, middle cerebral artery occlusion in conditions of unprevented, ischemia- induced fever. Phytother Res 2006; 20:438-43. [PMID: 16619358]
5. Shah ZA, Nada SE, Dore S. Heme oxygenase 1, beneficial role in permanent ischemic stroke and in Gingko biloba (EGb 761) neuroprotection. Neuroscience 2011; 180:248-55. [PMID: 21334424]
6. Chung SY, Cheng FC, Lee MS, Lin JY, Lin MC, Wang MF. Ginkgo biloba leaf extract (EGb761) combined with neuroprotective agents reduces the infarct volumes of gerbil ischemic brain. Am J Chin Med 2006; 34:803-17. [PMID: 17080546]
7. Ritch R. Neuroprotection: is it already applicable to glaucoma therapy? Curr Opin Ophthalmol 2000; 11:78-84. [PMID: 10848224]
8. Flammer J. Glaucoma a guide for patients an introduction for care-providers a reference for quick information. Bern: Hans Huber; 2001.
9. Flammer J, Orgul S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, Renard JP, Stefansson E. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res 2002; 21:359-93. [PMID: 12150988]
10. Flammer J, Mozaffarieh M. What is the present pathogenetic concept of glaucomatous optic neuropathy? Surv Ophthalmol 2007; 52:S162-73. misctextPMID: 17998042/misctext
11. Ou HC, Lee WJ, Lee IT, Chiu TH, Tsai KL, Lin CY, Sheu WH. Ginkgo biloba extract attenuates oxLDL-induced oxidative functional damages in endothelial cells. J Appl Physiol 2009; 106:1674-85. [PMID: 19228986]
12. Eckert A, Keil U, Scherping I, Hauptmann S, Muller WE. Stabilization of Mitochondrial Membrane Potential and Improvement of Neuronal Energy Metabolism by Ginkgo Biloba Extract EGb 761. Ann N Y Acad Sci 2005; 1056:474-85. [PMID: 16387710]
13. Abu-Amero KK, Morales J, Bosley TM. Mitochondrial abnormalities in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2006; 47:2533-41. [PMID: 16723467]
14. Abdel-Kader R, Hauptmann S, Keil U, Scherping I, Leuner K, Eckert A, Muller WE. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol Res 2007; 56:493-502. [PMID: 17977008]
15. Varga E, Bodi A, Ferdinandy P, Droy-Lefaix MT, Blasig IE, Tosaki A. The protective effect of EGb 761 in isolated ischemic/reperfused rat hearts: a link between cardiac function and nitric oxide production. J Cardiovasc Pharmacol 1999; 34:711-7. [PMID: 10547088]
16. Sofi F, Mannini L, Marcucci R, Bolli P, Sodi A, Giambene B, Menchini U, Gensini GF, Abbate R, Prisco D. Role of haemorheological factors in patients with retinal vein occlusion. Thromb Haemost 2007; 98:1215-9. [PMID: 18064316]
17. Huang SY, Jeng C, Kao SC, Yu JJ, Liu DZ. Improved haemorrheological properties by Ginkgo biloba extract (Egb 761) in type 2 diabetes mellitus complicated with retinopathy. Clin Nutr 2004; 23:615-21. [PMID: 15297098]
18. Sasaki Y, Noguchi T, Yamamoto E, Giddings JC, Ikeda K, Yamori Y, Yamamoto J. Effects of Ginkgo biloba extract (EGb 761) on cerebral thrombosis and blood pressure in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2002; 29:963-7. [PMID: 12366386]
19. Wu Y, Li S, Cui W, Zu X, Du J, Wang F. Ginkgo biloba extract improves coronary blood flow in healthy elderly adults: role of endothelium-dependent vasodilation. Phytomedicine 2008; 15:164-9. [PMID: 18258419]
20. Flammer J, Pache M, Resink T. Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. Prog Retin Eye Res 2001; 20:319-49. [PMID: 11286896]
21. Bayar MA, Erdem Y, Ozturk K, Bescalti O, Caydere M, Yucel D, Buharali Z, Ustun H. The effect of EGb-761 on morphologic vasospasm in canine basilar artery after subarachnoid hemorrhage. J Cardiovasc Pharmacol 2003; 42:395-402. [PMID: 12960685]
22. Russell P, Johnson DH. Enzymes protective of oxidative damage present in all decades of life in the trabecular meshwork, as detected by two-dimensional gel electrophoresis protein maps. J Glaucoma 1996; 5:317-24. [PMID: 8897231]
23. Saccà SC, Izzotti A, Rossi P, Traverso C. Glaucomatous outflow pathway and oxidative stress. Exp Eye Res 2007; 84:389-99. [PMID: 17196589]
24. Ueda J, Wentz-Hunter K, Yue BY. Distribution of myocilin and extracellular matrix components in the juxtacanalicular tissue of human eyes. Invest Ophthalmol Vis Sci 2002; 43:1068-76. [PMID: 11923248]
25. Zhou L, Li Y, Yue BY. Oxidative stress affects cytoskeletal structure and cell-matrix interactions in cells from an ocular tissue: the trabecular meshwork. J Cell Physiol 1999; 180:182-9. [PMID: 10395288]
26. Spector A, Garner WH. Hydrogen peroxide and human cataract. Exp Eye Res 1981; 33:673-81. [PMID: 7318962]
27. Rose RC, Richer SP, Bode AM. Ocular oxidants and antioxidant protection. Proc Soc Exp Biol Med 1998; 217:397-407. [PMID: 9521086]
28. Li AF, Tane N, Roy S. Fibronectin overexpression inhibits trabecular meshwork cell monolayer permeability. Mol Vis 2004; 10:750-7. [PMID: 15496827]
29. Wentz-Hunter K, Shen X, Okazaki K, Tanihara H, Yue BY. Overexpression of myocilin in cultured human trabecular meshwork cells. Exp Cell Res 2004; 297:39-48. [PMID: 15194423]
30. Kahn MG, Giblin FJ, Epstein DL. Glutathione in calf trabecular meshwork and its relation to aqueous humor outflow facility. Invest Ophthalmol Vis Sci 1983; 24:1283-7. [PMID: 6885312]
31. Izzotti A, Sacca SC, Cartiglia C, De FS. Oxidative deoxyribonucleic acid damage in the eyes of glaucoma patients. Am J Med 2003; 114:638-46. [PMID: 12798451]
32. Saccà SC, Pascotto A, Camicione P, Capris P, Izzotti A. Oxidative DNA damage in the human trabecular meshwork: clinical correlation in patients with primary open-angle glaucoma. Arch Ophthalmol 2005; 123:458-63. [PMID: 15824217]
33. Abu-Amero KK, Morales J, Bosley TM. Mitochondrial abnormalities in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2006; 47:2533-41. [PMID: 16723467]
34. Alvarado J, Murphy C, Juster R. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. Ophthalmology 1984; 91:564-79. [PMID: 6462622]
35. Scurti D, L'Abbate N, Capozzi D, Lofrumento R, Crivellini S, Ambrosi L. Ocular hypertension in radiologists and radiology technicians. Med Lav 1992; 83:330-7. [PMID: 1461191]
36. Haefliger IO, Dettmann E, Liu R, Meyer P, Prunte C, Messerli J, Flammer J. Potential role of nitric oxide and endothelin in the pathogenesis of glaucoma. Surv Ophthalmol 1999; 43:S51-8. misctextPMID: 10416747/misctext
37. Ferreira SM, Lerner SF, Brunzini R, Evelson PA, Llesuy SF. Oxidative stress markers in aqueous humor of glaucoma patients. Am J Ophthalmol 2004; 137:62-9. [PMID: 14700645]
38. Gherghel D, Griffiths HR, Hilton EJ, Cunliffe IA, Hosking SL. Systemic reduction in glutathione levels occurs in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2005; 46:877-83. [PMID: 15728543]
39. Yang J, Tezel G, Patil RV, Romano C, Wax MB. Serum autoantibody against glutathione S-transferase in patients with glaucoma. Invest Ophthalmol Vis Sci 2001; 42:1273-6. [PMID: 11328739]
40. Wang N, Chintala SK, Fini ME, Schuman JS. Activation of a tissue-specific stress response in the aqueous outflow pathway of the eye defines the glaucoma disease phenotype. Nat Med 2001; 7:304-9. [PMID: 11231628]
41. Richer SP, Rose RC. Water soluble antioxidants in mammalian aqueous humor: interaction with UV B and hydrogen peroxide. Vision Res 1998; 38:2881-8. [PMID: 9797984]
42. Tamm ER, Russell P, Johnson DH, Piatigorsky J. Human and monkey trabecular meshwork accumulate alpha B-crystallin in response to heat shock and oxidative stress. Invest Ophthalmol Vis Sci 1996; 37:2402-13. [PMID: 8933757]
43. Kaiser HJ, Schoetzau A, Stumpfig D, Flammer J. Blood-flow velocities of the extraocular vessels in patients with high- tension and normal-tension primary open-angle glaucoma. Am J Ophthalmol 1997; 123:320-7. [PMID: 9063241]
44. Mozaffarieh M, Grieshaber MC, Flammer J. Oxygen and blood flow: players in the pathogenesis of glaucoma. Mol Vis 2008; 14:224-33. [PMID: 18334938]
45. Hernandez MR, Miao H, Lukas T. Astrocytes in glaucomatous optic neuropathy. Prog Brain Res 2008; 173:353-73. [PMID: 18929121]
46. Flammer J. Normal-pressure glaucoma. Fortschr Ophthalmol 1990; 87:S187-9. misctextPMID: 2083901/misctext
47. Quigley HA, Cone FE, Gelman SE, Yang Z, Son JL, Oglesby EN, Pease ME, Zack DJ. Lack of neuroprotection against experimental glaucoma in c-Jun N-terminal kinase 3 knockout mice. Exp Eye Res 2011; 92:299-305. [PMID: 21272576]
48. Millar JC, Clark AF, Pang IH. Assessment of aqueous humor dynamics in the mouse by a novel method of constant-flow infusion. Invest Ophthalmol Vis Sci 2011; 52:685-94. [PMID: 20861483]
49. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retin Eye Res 2006; 25:490-513. [PMID: 16962364]
50. Ganapathy PS, White RE, Ha Y, Bozard BR, McNeil PL, Caldwell RW, Kumar S, Black SM, Smith SB. The role of N- methyl-D-aspartate receptor activation in homocysteine- induced death of retinal ganglion cells. Invest Ophthalmol Vis Sci 2011; 52:5515-24. [PMID: 21436276]
51. Li GY, Fan B, Su GF. Acute energy reduction induces caspase- dependent apoptosis and activates p53 in retinal ganglion cells (RGC-5). Exp Eye Res 2009; 89:581-9. [PMID: 19524568]
52. Iizuka Y, Hong S, Kim CY, Kim SK, Seong GJ. Agmatine pretreatment protects retinal ganglion cells (RGC-5 cell line) from oxidative stress in vitro. Biocell 2008; 32:245-50. [PMID: 19181187]
53. Williams D, Norman G, Khoury C, Metcalfe N, Briard J, Laporte A, Sheibani S, Portt L, Mandato CA, Greenwood MT. Evidence for a second messenger function of dUTP during Bax mediated apoptosis of yeast and mammalian cells. Biochim Biophys Acta 2011; 1813:315-321. [PMID: 21145358]
54. Wang F, Zhai H, Huang L, Li H, Xu Y, Qiao X, Sun S, Wu Y. Aspirin Protects Dopaminergic neurons against lipopolysaccharide-induced neurotoxicity in primary midbrain cultures. J Mol Neurosci 2012; 46:153-61. [PMID: 21584653]
55. Patel VP, Chu CT. Nuclear transport, oxidative stress, and neurodegeneration. Int J Clin Exp Pathol 2011; 4:215-29. [PMID: 21487518]
56. Kaur H, Chauhan S, Sandhir R. Protective effect of lycopene on oxidative stress and cognitive decline in rotenone induced model of Parkinson's disease. Neurochem Res 2011; 36:1435-43. [PMID: 21484267]
57. Allaman I, Gavillet M, Belanger M, Laroche T, Viertl D, Lashuel HA, Magistretti PJ. Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability. J Neurosci 2010; 30:3326-38. [PMID: 20203192]
58. Fitzgerald M, Bartlett CA, Payne SC, Hart NS, Rodger J, Harvey AR, Dunlop SA. Near infrared light reduces oxidative stress and preserves function in CNS tissue vulnerable to secondary degeneration following partial transection of the optic nerve. J Neurotrauma 2010; 27:2107-19. [PMID: 20822460]
59. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107:1058-70. [PMID: 21030723]
60. Del RR, Moya EA, Iturriaga R. Differential expression of pro- inflammatory cytokines, endothelin-1 and nitric oxide synthases in the rat carotid body exposed to intermittent hypoxia. Brain Res 2011; 1395:74-85. [PMID: 21555119]
61. Mozaffarieh M, Grieshaber MC, Orgul S, Flammer J. The potential value of natural antioxidative treatment in glaucoma. Surv Ophthalmol 2008; 53:479-505. [PMID: 18929760]
62. Kong GY, Van Bergen NJ, Trounce IA, Crowston JG. Mitochondrial dysfunction and glaucoma. J Glaucoma 2009; 18:93-100. [PMID: 19225343]
63. Osborne NN. Pathogenesis of ganglion "cell death" in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria. Prog Brain Res 2008; 173:339-52. [PMID: 18929120]
64. Zhang J, Fu S, Liu S, Mao T, Xiu R. The therapeutic effect of Ginkgo biloba extract in SHR rats and its possible mechanisms based on cerebral microvascular flow and vasomotion. Clin Hemorheol Microcirc 2000; 23:133-8. [PMID: 11321432]
65. Flammer J. Glaucomatous optic neuropathy: a reperfusion injury. Klin Monatsbl Augenheilkd 2001; 218:290-1. [PMID: 11417319]
66. Szabo ME, Droy-Lefaix MT, Doly M. Direct measurement of free radicals in ischemic/reperfused diabetic rat retina. Clin Neurosci 1997; 4:240-5. [PMID: 9292250]
67. Hao Y, Sun Y, Xu C, Jiang X, Sun H, Wu Q, Yan C, Gu S. Improvement of contractile function in isolated cardiomyocytes from ischemia-reperfusion rats by ginkgolide B pretreatment. J Cardiovasc Pharmacol 2009; 54:3-9. [PMID: 19487958]
68. Uhler TA, Piltz-Seymour J. Optic disc hemorrhages in glaucoma and ocular hypertension: implications and recommendations. Curr Opin Ophthalmol 2008; 19:89-94. [PMID: 18301280]
69. Bengtsson B, Leske MC, Yang Z, Heijl A. Disc hemorrhages and treatment in the early manifest glaucoma trial. Ophthalmology 2008; 115:2044-8. [PMID: 18692244]
70. Kotil K, Uyar R, Bilge T, Ton T, Kucukhuseyin C, Koldas M, Atay F. Investigation of the dose-dependent antivasospasmic effect of Ginkgo biloba extract (EGb 761) in experimental subarachnoid hemorrhage. J Clin Neurosci 2008; 15:1382-6. [PMID: 18951801]
71. Hirooka K, Tokuda M, Miyamoto O, Itano T, Baba T, Shiraga F. The Ginkgo biloba extract (EGb 761) provides a neuroprotective effect on retinal ganglion cells in a rat model of chronic glaucoma. Curr Eye Res 2004; 28:153-7. [PMID: 14977516]
72. Ritch R. Complementary therapy for the treatment of glaucoma: a perspective. Ophthalmol Clin North Am 2005; 18:597-609. [PMID: 16314222]
73. Ritch R. Potential role for Ginkgo biloba extract in the treatment of glaucoma. Med Hypotheses 2000; 54:221-35. [PMID: 10790757]
74. Galassi F, Sodi A, Ucci F, Renieri G, Pieri B, Baccini M. Ocular hemodynamics and glaucoma prognosis: a color Doppler imaging study. Arch Ophthalmol 2003; 121:1711-5. [PMID: 14662590]
75. Schumann J, Orgul S, Gugleta K, Dubler B, Flammer J. Interocular difference in progression of glaucoma correlates with interocular differences in retrobulbar circulation. Am J Ophthalmol 2000; 129:728-33. [PMID: 10926980]
76. Satilmis M, Orgul S, Doubler B, Flammer J. Rate of progression of glaucoma correlates with retrobulbar circulation and intraocular pressure. Am J Ophthalmol 2003; 135:664-9. [PMID: 12719074]
77. Chung HS, Harris A, Kristinsson JK, Ciulla TA, Kagemann C, Ritch R. Ginkgo biloba extract increases ocular blood flow velocity. J Ocul Pharmacol Ther 1999; 15:233-40. [PMID: 10385132]
78. Mozaffarieh M, Flammer J. Is there more to glaucoma treatment than lowering IOP? Surv Ophthalmol 2007; 52:S174-9. [PMID: 17998043]
79. Flammer J, Drance SM. Effect of acetazolamide on the differential threshold. Arch Ophthalmol 1983; 101:1378-80. [PMID: 6615301]
80. Flammer J, Drance SM. Reversibility of a glaucomatous visual field defect after acetazolamide therapy. Can J Ophthalmol 1983; 18:139-41. [PMID: 6871793]
81. Gaspar AZ, Flammer J, Hendrickson P. Influence of nifedipine on the visual fields of patients with optic-nerve-head diseases. Eur J Ophthalmol 1994; 4:24-8. [PMID: 8019119]
82. Quaranta L, Bettelli S, Uva MG, Semeraro F, Turano R, Gandolfo E. Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma. Ophthalmology 2003; 110:359-62. [PMID: 12578781]
83. DeKosky ST, Fitzpatrick A, Ives DG, Saxton J, Williamson J, Lopez OL, Burke G, Fried L, Kuller LH, Robbins J, Tracy R, Woolard N, Dunn L, Kronmal R, Nahin R, Furberg C. The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp Clin Trials 2006; 27:238-53. [PMID: 16627007]
84. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997; 278:1327-32. [PMID: 9343463]
85. Taillandier J, Ammar A, Rabourdin JP, Ribeyre JP, Pichon J, Niddam S, Pierart H. Treatment of cerebral aging disorders with Ginkgo biloba extract. A longitudinal multicenter double-blind drug vs. placebo study. Presse Med 1986; 15:1583-7. [PMID: 2947106]
86. McKenna DJ, Jones K, Hughes K. Efficacy, safety, and use ofginkgo biloba in clinical and preclinical applications. Altern Ther Health Med 2001; 7:70-86. [PMID: 11565403]
87. Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature: a case report and systematic review of the literature. J Gen Intern Med 2005; 20:657-61. [PMID: 16050865]
88. Köhler S, Funk P, Kieser M. Influence of a 7-day treatment with Ginkgo biloba special extract EGb 761 on bleeding time and coagulation: a randomized, placebo-controlled, double-blind study in healthy volunteers. Blood Coagul Fibrinolysis 2004; 15:303-9. [PMID: 15166915]
89. Bal Dit Sollier C, Caplain H, Drouet L. No alteration in platelet function or coagulation induced by EGb761 in a controlled study. Clin Lab Haematol 2003; 25:251-3. [PMID: 12890165]
90. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, Kuller LH, Robbins JA, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL, Furberg CD. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008; 300:2253-62. [PMID: 19017911]
91. Dodge HH, Zitzelberger T, Oken BS, Howieson D, Kaye J. A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. Neurology 2008; 70:1809-17. [PMID: 18305231]
92. Brinker F. July, 2005 edited excerpts from: complex herbs- complete medicines, Eclectic Medical Publications, Sandy, OR, 2004. J Herb Pharmacother 2005; 5:63-9. [PMID: 16635969]
93. Wolf HR. Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily? Drugs R D 2006; 7:163-72. [PMID: 16752942]
94. Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thromb Haemost 2002; 87:1075-6. [PMID: 12083489]
95. Jiang X, Blair EY, McLachlan AJ. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. J Clin Pharmacol 2006; 46:1370-8. [PMID: 17050802]